A Phase II study of combination chemotherapy with TS-1 and Trastuzumab for patients with HER2 positive advanced or recurrent gastric cancer. - STAR study

Osaka medical center for cancer and cardiovascular diseases0 个研究点目标入组 20 人开始时间: 2012年6月20日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Prior chemotherapy of TS-1 2) With severe allergy to TS-1 and Trastuzumab 3) Women in pregnancy, at risk of pregnancy, hoping to become pregnant. Men who want their partners to become pregnant. 4) Active infection and inflammation. 5) History of cardiac disease 6) Patients with Severe complications 7) Patients with resting dyspnea 8) Patients with gastrointestinal ulceration and bleed 9) Patients with diarrhea (4 or more times per day or watery diarrhea). 10) Massive pleural or abdominal effusion 11) Patients with metastasis to CNS 12) synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ 13) Patients under treatment with flucytosine, phenytoin or warfarin potassium 14) Patients who are received systemic administration of corticosteroid. 15) Other patients who are unfit for the study as determined by the attending physician.

发起方

Osaka medical center for cancer and cardiovascular diseases